Browse by category

Vanda Pharmaceuticals has announced positive topline results from its randomised controlled clinical study (VP-VLY-686-2601) evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy in overweight and obese adults. This study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg injection of Wegovy, a dose that normally takes 9 weeks of titrat